{"groups":[{"description":"Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.\n\nPegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide.\n\nRituximab: 375 mg/m\\^2/day on Days 1, 4, 8, 11, 45, and 52.\n\nCyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.","id":"FG000","title":"R-HiCy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"81"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"70"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"16 participants were screen failures. IRB allowed 3 of those participants to be analyzed along with the 78 who were treated as part of the study. Because the 3 additional participants received the exact same protocol intervention, the total population for analysis purposes is 81."}